RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2024 · 81 positions · Total reported value $8.67B · Top-10 concentration 55.2% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2024 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 81 equity positions with a combined reported value of $8.67B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.2% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were ASND ($1.45B), PCVX ($992.91M), JANX ($416.40M). By sector, the heaviest allocations are Health Care 83.9%, Consumer Discretionary 2.8%. Versus the prior quarter, allocation shifted toward Consumer Discretionary (+0.6pp).

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 83% of names.

The largest new positions opened in Q3 2024 were BCAX ($177.17M), ARTV ($152.23M), BIOA ($45.98M).

Of the 11 positions fully exited versus the prior quarter, the largest were LBPH ($88.90M), URGN ($51.74M), NRIX ($13.57M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • BCAX BICARA THERAPEUTICS INC · $177.17M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $152.23M
  • BIOA BIOAGE LABS INC · $45.98M
  • IDYA IDEAYA BIOSCIENCES INC · $42.68M
  • MBX MBX BIOSCIENCES INC · $39.26M
  • XNCR XENCOR INC · $11.56M
  • AVTX AVALO THERAPEUTICS INC · $9.19M
  • CDTX CIDARA THERAPEUTICS INC COM NEW · $7.56M

Fully Exited (vs previous quarter)

  • LBPH LONGBOARD PHARMACEUTICALS IN · prev qtr: $88.90M
  • URGN UROGEN PHARMA LTD · prev qtr: $51.74M
  • NRIX NURIX THERAPEUTICS INC · prev qtr: $13.57M
  • CYBN CYBIN INC · prev qtr: $11.93M
  • MGNX MACROGENICS INC · prev qtr: $8.85M
  • UNCY UNICYCIVE THERAPEUTICS INC · prev qtr: $1.32M

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

Sector Allocation

Health Care 83.9%
Materials 0.0%
Other 13.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 9.71M $1.45B 16.72%
16.72%
Reduce
2 8.69M $992.91M 11.45%
11.45%
Add
3 9.17M $416.40M 4.80%
4.80%
Hold
4 7.51M $365.81M 4.22%
4.22%
Hold
5 6.08M $318.76M 3.67%
3.67%
Hold
6 6.30M $289.38M 3.34%
3.34%
Add
7 10.42M $244.89M 2.82%
2.82%
Hold
8 8.51M $240.80M 2.78%
2.78%
Hold
9 8.91M $237.78M 2.74%
2.74%
Hold
10 1.18M $229.59M 2.65%
2.65%
Add
11 6.38M $229.21M 2.64%
2.64%
Add
12 3.92M $193.61M 2.23%
2.23%
Add
13 6.96M $177.17M 2.04%
2.04%
New
14 31.42M $159.92M 1.84%
Form 4 · 4 →
1.84%
Hold
15 10.86M $157.48M 1.82%
1.82%
Hold
16 1.85M $154.62M 1.78%
1.78%
Add
17 9.85M $152.23M 1.75%
1.75%
New
18 18.20M $149.26M 1.72%
Form 4 · 1 →
1.72%
Hold
19 32.29M $146.58M 1.69%
1.69%
Reduce
20 5.01M $144.13M 1.66%
1.66%
Reduce
21 8.06M $133.86M 1.54%
1.54%
Hold
22 1.96M $115.24M 1.33%
1.33%
Hold
23 7.87M $109.65M 1.26%
1.26%
Hold
24 14.18M $104.90M 1.21%
1.21%
Hold
25 15.38M $101.38M 1.17%
1.17%
Hold
26 4.18M $99.21M 1.14%
Form 4 · 3 →
1.14%
Hold
27 10.69M $91.40M 1.05%
1.05%
Hold
28 1.00M $89.87M 1.04%
1.04%
Hold
29 1.90M $83.25M 0.96%
0.96%
Hold
30 2.54M $65.28M 0.75%
0.75%
Hold
31 2.33M $63.88M 0.74%
0.74%
Hold
32 4.85M $58.75M 0.68%
0.68%
Hold
33 8.34M $58.38M 0.67%
0.67%
Hold
34 5.11M $56.21M 0.65%
0.65%
Add
35 5.10M $55.11M 0.64%
0.64%
Hold
36 1.40M $52.73M 0.61%
0.61%
Hold
37 2.25M $50.99M 0.59%
0.59%
Hold
38 10.81M $48.84M 0.56%
0.56%
Hold
39 2.21M $45.98M 0.53%
0.53%
New
40 6.69M $44.73M 0.52%
0.52%
Add
41 761.96K $43.84M 0.51%
0.51%
Reduce
42 1.35M $42.68M 0.49%
0.49%
New
43 6.05M $39.60M 0.46%
0.46%
Hold
44 1.51M $39.26M 0.45%
0.45%
New
45 14.93M $37.03M 0.43%
0.43%
Hold
46 10.23M $36.52M 0.42%
0.42%
Reduce
47 3.18M $32.52M 0.38%
0.38%
Reduce
48 4.33M $30.18M 0.35%
0.35%
Hold
49 4.88M $27.80M 0.32%
0.32%
Hold
50 1.06M $27.10M 0.31%
0.31%
Reduce

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2024-Q3?

In its 2024-Q3 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 81 equity positions worth $8.67B in aggregate; its largest disclosed positions were ASND ($1.45B), PCVX ($992.91M), JANX ($416.40M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $8.67B of long equity holdings across 81 positions as of 2024-Q3. Top-10 holdings account for 55.2% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →